HOME >> MEDICINE >> NEWS
MIT graduate student wins $30,000 Lemelson-MIT student prize for life-saving inventions

CAMBRIDGE, Mass. (February 14, 2007) The ability to leap tall buildings in a single bound used to be the stuff of comic-book fantasy. Nathan Ball, a 23-year-old graduate student at the Massachusetts Institute of Technology and this years winner of the $30,000 Lemelson-MIT Student Prize, has invented a device that makes the fantasy a reality.

With the help of Balls ATLAS Powered Rope Ascender, a fully loaded firefighter could reach the top of a 30-story building in only 30 seconds, compared to the six minutes or more it often takes to trudge up stairs with 80 to 100 pounds of equipment. The device, which is the size of a hand-held power tool, can lift a 250-pound load more than 600 feet into the air at nearly 10 feet per second, all on a single battery charge.

Ingenuity, creativity and passion seem to course through Nates blood, said Merton Flemings, director of the Lemelson-MIT Program, which sponsors the annual award. His battery-powered rope ascender and needle-free injection technology both have life-saving capabilities and many commercial applications.

Nate is also an inspiring and committed mentor for young inventors. This combination of attributes made him our top choice for this years $30,000 Lemelson-MIT Student Prize, Flemings added.

Up, Up and Away!

In November 2004, Ball and three colleagues entered the Soldier Design Competition sponsored by the MIT Institute for Soldier Nanotechnologies. The competition called for a high-powered device to enable rapid vertical mobility.

Ball called the challenge unprecedented, as the original specifications called for a device that weighed less than 25 pounds and could lift 250 pounds 50 feet into the air, in five seconds. Thats more than five horsepower in a 25-pound package, he explained. Thats a power-to-weight ratio higher than a Dodge Vipers we did the math. To have that much power in that small of a package is a heck of a challenge.


'"/>

Contact: Matt Paine
mpaine@coneinc.com
617-939-8314
Lemelson-MIT Program
14-Feb-2007


Page: 1 2 3 4

Related medicine news :

1. AACR-Bardos Awards for undergraduate students announced
2. Where are medical graduates practising and why?
3. Decline in performance of candidates taking a postgraduate medical examination between 1997 and 2001
4. Brief motivational interviews work best long term for college students sent to alcohol counseling
5. Medical students respond positively to simulated patient experience
6. Early-morning Friday classes may prevent students from getting sloppy on thirsty Thursdays
7. New nutritional research: College students face obesity, high blood pressure, metabolic syndrome
8. Going to bed late may affect the health, academic performance of college students
9. College students who pull all-nighters and get no sleep more likely to have a lower GPA
10. Study examines characteristics of female high school students who report steroid use
11. Binge drinking leads to neurocognitive deficits among college students

Post Your Comments:
(Date:4/22/2014)... percent of all lung cancers are small cell ... develop resistance to chemotherapy. However, researchers at Virginia ... insights into the mechanisms leading to this resistance ... Chemotherapies work primarily by mediating B-cell lymphoma 2 ... cell death. Depending on their function, this family ...
(Date:4/22/2014)... 2014Hemoglobin A1c is the standard measurement for assessing glycemic ... of A1c are typically measured every few months in ... model that accurately estimates A1c using self-monitored blood glucose ... Therapeutics ( DTT ), a peer-reviewed journal from ... free on the DTT website at ...
(Date:4/22/2014)... PHILADELPHIA (April 22, 2014) That person we all seem ... take action? Turns out he or she isn,t unable to ... A study of nearly ... about why neurotic people may avoid making decisions and moving ... if action is positive, favorable, good, they just don,t like ...
(Date:4/22/2014)... -- In parallel with modern man ( Homo sapiens ), ... we lived side by side, such as Neanderthals and the ... sapiens survived. What was it in our genetic makeup ... little is known about our unique genetic makeup as distinguished ... fact that we are the only species among them ,to ...
(Date:4/22/2014)... Disease (IBD), a group of chronic inflammatory disorders of ... affects over 1.4 million people in the U.S., and ... there is no cure. , Now, Cincinnati Cancer ... Susan Waltz, PhD, and scientists in her lab have ... genetic study to document the important function for the ...
Breaking Medicine News(10 mins):Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Neurotics don't just avoid action: They dislike it 2Health News:What gave us the advantage over extinct types of humans? 2Health News:Two genes linked to inflammatory bowel disease 2
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: